ATE135214T1 - Darreichungsformen mit verlaengerter wirkstoffreigabe - Google Patents
Darreichungsformen mit verlaengerter wirkstoffreigabeInfo
- Publication number
- ATE135214T1 ATE135214T1 AT93810066T AT93810066T ATE135214T1 AT E135214 T1 ATE135214 T1 AT E135214T1 AT 93810066 T AT93810066 T AT 93810066T AT 93810066 T AT93810066 T AT 93810066T AT E135214 T1 ATE135214 T1 AT E135214T1
- Authority
- AT
- Austria
- Prior art keywords
- dosage forms
- weight
- extended release
- calcium antagonist
- dihydropyridine type
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 238000013265 extended release Methods 0.000 title 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 2
- 239000000480 calcium channel blocker Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000007888 film coating Substances 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH46992 | 1992-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE135214T1 true ATE135214T1 (de) | 1996-03-15 |
Family
ID=4187725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93810066T ATE135214T1 (de) | 1992-02-17 | 1993-02-03 | Darreichungsformen mit verlaengerter wirkstoffreigabe |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0557244B1 (de) |
| AT (1) | ATE135214T1 (de) |
| DE (1) | DE69301742T2 (de) |
| DK (1) | DK0557244T3 (de) |
| ES (1) | ES2084478T3 (de) |
| GR (1) | GR3019314T3 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5393765A (en) * | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
| NZ270439A (en) * | 1995-02-02 | 1996-04-26 | Bernard Charles Sherman | Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer |
| NZ286451A (en) * | 1996-04-24 | 1998-04-27 | Bernard Charles Sherman | Controlled release pharmaceutical composition containing granules comprising drug, water-insoluble polymer and meltable carrier |
| RU2219927C1 (ru) * | 2002-11-21 | 2003-12-27 | Азад Зияд Оглы Абышев | Анкардин-retard - средство пролонгированного антикальциевого действия |
| RU2255728C1 (ru) * | 2004-03-04 | 2005-07-10 | Азад Зияд Оглы Абышев | Средство пролонгированного антикальциевого действия в виде 0,1% раствора для внутривенного введения |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4571333A (en) * | 1983-06-14 | 1986-02-18 | Syntex (U.S.A.) Inc. | Controlled release naproxen and naproxen sodium tablets |
| JPS6038322A (ja) * | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンa物質含有易溶性固形製剤 |
| JPS6124516A (ja) * | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | 持続性錠剤 |
| IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
| IE59540B1 (en) * | 1987-01-09 | 1994-03-09 | Elan Corp | Sustained release capsule or tablet formulation |
| GB8722306D0 (en) * | 1987-09-22 | 1987-10-28 | Aps Research Ltd | Sustained-release formulation |
| SI8810082A8 (en) * | 1988-01-18 | 1995-12-31 | Lek Tovarna Farmacevtskih | Process for preparing new inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrine |
| DE3814532A1 (de) * | 1988-04-29 | 1989-11-09 | Bayer Ag | Dhp-retard-zubereitung |
-
1993
- 1993-02-03 AT AT93810066T patent/ATE135214T1/de not_active IP Right Cessation
- 1993-02-03 EP EP93810066A patent/EP0557244B1/de not_active Expired - Lifetime
- 1993-02-03 ES ES93810066T patent/ES2084478T3/es not_active Expired - Lifetime
- 1993-02-03 DE DE69301742T patent/DE69301742T2/de not_active Expired - Fee Related
- 1993-02-03 DK DK93810066.6T patent/DK0557244T3/da active
-
1996
- 1996-03-14 GR GR960400505T patent/GR3019314T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2084478T3 (es) | 1996-05-01 |
| EP0557244A1 (de) | 1993-08-25 |
| DE69301742D1 (de) | 1996-04-18 |
| DK0557244T3 (da) | 1996-04-01 |
| GR3019314T3 (en) | 1996-06-30 |
| EP0557244B1 (de) | 1996-03-13 |
| DE69301742T2 (de) | 1996-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU93004469A (ru) | Формы дозирования, обеспечивающие продленное выделение активного ингредиента | |
| GEP20012549B (en) | Pharmaceutical Composition Containing Sumatriptan | |
| HU0200688D0 (en) | Pharmaceutical formulations with improved release containing solid salts of racemic thioctic acid | |
| EP2103303A3 (de) | Tramadolhaltige Formulierung mit gesteuerter Freisetzung | |
| CA2131350A1 (en) | Sustained release drug formulation containing a tramadol salt | |
| DE69523438D1 (de) | Orale metoprolol-dosisform des typs "einmal täglich" | |
| FI961996A0 (fi) | Pitkitetysti vapauttavat valmisteet metoprololin 24 tunnin pituiseksi vapauttamiseksi | |
| CA2240329A1 (en) | Improved delivery of multiple doses of medications | |
| CA2387705A1 (en) | Stable pharmaceutical composition for oral use | |
| EP0700284A4 (de) | Oxybutyninformulierungen mit gesteuerter freisetzung | |
| NZ216082A (en) | Prolonged-release microparticles | |
| KR950703937A (ko) | 안정한 서방성 경구 투여 조성물(Stable extended release oral dosage composition) | |
| FI933274A0 (fi) | Tvaerbundna, kvaevehaltiga vinylkopolymerer, foerfarande foer framstaellning av dessa samt anvaendning av dessa | |
| NO306654B1 (no) | Farmasöytisk preparat inneholdende diklormetylenbisfosfonsyre eller salt derav for oral tilförsel | |
| DE69622739D1 (de) | Pharmazeutische zubereitung mit schneller freisetzung | |
| DE69723024D1 (de) | Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff | |
| ATE135214T1 (de) | Darreichungsformen mit verlaengerter wirkstoffreigabe | |
| DE69209916D1 (de) | Oral anzuwendende Arzneimittel Dapiprazol enthaltend | |
| IL113167A0 (en) | A sustained release pharmaceutical excipient containing a heteropolysaccharide gum and methods for the preparation thereof | |
| GB9420748D0 (en) | 1,5 benzodiazepine derivatives | |
| EP0761209A3 (de) | Ranitidinformulierungen mit gesteuerter Freisetzung | |
| ATE165599T1 (de) | Benzospiroalken-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| ATE175870T1 (de) | Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner | ||
| EEFA | Change of the company name | ||
| REN | Ceased due to non-payment of the annual fee |